American pharmaceutical company Moderna is renouncing the patent on its coronavirus vaccine in 92 low- and middle-income countries, the company announced on Tuesday.
Specifically, it concerns the countries that participate in the World Health Organisation’s (WHO) Covax programme, aimed at equitable access to Covid-19 vaccines.
However, the company stated that it pledged never to enforce its patents in those countries, provided that the manufactured vaccines are only being used in those 92 countries.
— Moderna (@moderna_tx) March 8, 2022
On Monday, Moderna already announced that it wants to set up a coronavirus factory in Kenya. The pharmaceutical company will invest $500 million (€460 million) in the production site, which will produce mRNA vaccines for the African continent.